Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of specific share transactions rather than a financial performance report.
Material Changes
The filing reports an increase in interest in Ordinary Share ADRs by Mr. E J Gray. This transaction occurred on February 14, 2008, at a price of $54.11 per ADR. The increase resulted from the re-investment of the dividend paid to shareholders on January 10, 2008. The specific quantity of shares acquired is listed as 11.28.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of ADRs held by Mr. E J Gray following the 11.28 share increase.
- Confirm the dividend amount reinvested on January 10, 2008, to validate the transaction value.
- Check subsequent filings for any further changes in director holdings or incentive plan distributions.